Karyopharm to Participate at the Jefferies Global Healthcare Conference

Rhea-AI Summary

Karyopharm Therapeutics (Nasdaq: KPTI) announced that its senior management will participate in the Jefferies Global Healthcare Conference on June 5, 2024, in New York. The event includes a fireside chat at 1:00 p.m. ET. A live webcast and slides will be available on the company's website under the 'Events & Presentations' section and for replay afterward.

Positive

• Participation in a major conference could increase visibility and investor interest, potentially impacting stock positively.
• Accessibility of the webcast and slides provides transparent communication with investors.

Negative

• The press release lacks specific financial or clinical updates, which may be perceived as a lack of significant recent progress.
• No new product announcements or major business developments are revealed.

NEWTON, Mass., May 29, 2024 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that the Company's senior management team will participate at the Jefferies Global Healthcare Conference in a fireside chat on Wednesday, June 5, 2024 at 1:00 p.m. ET in New York, NY.

A live webcast of the event, along with accompanying slides, can be accessed under "Events & Presentations" in the Investor section of the Company's website, http://investors.karyopharm.com/events-presentations, and will be available for replay following the event.

About Karyopharm Therapeutics

Karyopharm Therapeutics Inc. (Nasdaq: KPTI) is a commercial-stage pharmaceutical company whose dedication to pioneering novel cancer therapies is fueled by a belief in the extraordinary strength and courage of patients with cancer. Since its founding, Karyopharm has been an industry leader in oral compounds that address nuclear export dysregulation, a fundamental mechanism of oncogenesis. Karyopharm's lead compound and first-in-class, oral exportin 1 (XPO1) inhibitor, XPOVIO® (selinexor), is approved in the U.S. and marketed by the Company in three oncology indications. It has also received regulatory approvals in various indications in a growing number of ex-U.S. territories and countries, including Europe and the United Kingdom (as NEXPOVIO®) and China. Karyopharm has a focused pipeline targeting indications in multiple high unmet need cancers, including in multiple myeloma, endometrial cancer, myelofibrosis, and diffuse large B-cell lymphoma (DLBCL). For more information about our people, science and pipeline, please visit www.karyopharm.com, and follow us on LinkedIn and on X at @Karyopharm.

XPOVIO® and NEXPOVIO® are registered trademarks of Karyopharm Therapeutics Inc. Any other trademarks referred to in this release are the property of their respective owners.

View original content to download multimedia:https://www.prnewswire.com/news-releases/karyopharm-to-participate-at-the-jefferies-global-healthcare-conference-302158124.html

SOURCE Karyopharm Therapeutics Inc.

FAQ

What event is Karyopharm (KPTI) participating in?

Karyopharm is participating in the Jefferies Global Healthcare Conference on June 5, 2024.

When is Karyopharm's fireside chat at the Jefferies Global Healthcare Conference?

Karyopharm's fireside chat is scheduled for June 5, 2024, at 1:00 p.m. ET.

Where can I access the webcast for Karyopharm's conference participation?

The webcast can be accessed in the 'Events & Presentations' section of Karyopharm's investor website, and it will be available for replay.

What is the stock symbol for Karyopharm Therapeutics?

The stock symbol for Karyopharm Therapeutics is KPTI.